Biosplice Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Biosplice Therapeutics, Inc. - overview
Established
2020
Location
San Diego, CA, US
Primary Industry
Biotechnology
About
Founded in 2020 and based in California, US, Biosplice Therapeutics, Inc. (Biosplice), formerly Samumed, LLC operates as a biotechnology company that develops therapeutics based on alternative pre-mRNA splicing for major diseases. In April 2021, the company received USD 120 million from Eventide Asset Management, aMoon, SymBiosis II, Sands Capital, Verition Fund Management, and others. The company offers small-molecule therapeutics based on the pioneering science of alternative pre-mRNA splicing a process that enables a messenger RNA (mRNA) to direct the synthesis of different protein variants intended to treat major diseases in osteoarthritis, oncology, and neurology.
Biosplice Therapeutics, Inc. plans to accelerate the development and launch of lorecivivint, a Phase 3 program in osteoarthritis.
Current Investors
Verition Fund Management, Eventide Asset Management, Sands Capital Alternatives
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.biosplice.com
Company Stage
Series B
Total Amount Raised
Subscriber access only
Biosplice Therapeutics, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.